# Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression

> **NCT04029428** · PHASE2 · UNKNOWN · sponsor: **University of Warmia and Mazury** · enrollment: 150 (estimated)

## Conditions studied

- Neuroendocrine Tumors

## Interventions

- **DRUG:** 90Y-DOTATATE
- **DRUG:** (177Lu-DOTAOTyr3)Octreotate
- **DRUG:** 90Y DOTATATE and 177Lu DOTATATE (mix each of 50%)

## Key facts

- **NCT ID:** NCT04029428
- **Lead sponsor:** University of Warmia and Mazury
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-11-02
- **Primary completion:** 2021-01-01
- **Final completion:** 2021-01-01
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2020-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04029428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04029428, "Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04029428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*